American Society of Hematology

Fig. 1.

$Fig. 1. Leukocyte rolling flux fraction and rolling velocities. / (A) Leukocyte rolling flux fraction in untreated cremaster venules. Effect of function-blocking mAbs on leukocyte rolling flux fraction (mean ± SEM) in venules of the cremaster muscle of C2GlcNAcT-I–deficient mice (▪) and control mice (░). * indicates significant differences (P < .05) in leukocyte rolling flux fraction between core 2−/− and control mice. (B) Leukocyte rolling velocities in venules of untreated core 2−/− and control mice. Data represent cumulative histograms of leukocyte rolling velocities measured during the first hour after exteriorization of the cremaster muscle. Velocity distribution for untreated core 2−/− mice (solid line, 113 cells), untreated control mice (dotted line, 44 cells), and control mice treated with PSGL-1–blocking mAb 4RA10 (dashed line, 114 cells). Core2−/− mice treated with 4RA10 showed no rolling.$

Leukocyte rolling flux fraction and rolling velocities.

(A) Leukocyte rolling flux fraction in untreated cremaster venules. Effect of function-blocking mAbs on leukocyte rolling flux fraction (mean ± SEM) in venules of the cremaster muscle of C2GlcNAcT-I–deficient mice (▪) and control mice (░). * indicates significant differences (P < .05) in leukocyte rolling flux fraction between core 2^−/− and control mice. (B) Leukocyte rolling velocities in venules of untreated core 2^−/− and control mice. Data represent cumulative histograms of leukocyte rolling velocities measured during the first hour after exteriorization of the cremaster muscle. Velocity distribution for untreated core 2^−/− mice (solid line, 113 cells), untreated control mice (dotted line, 44 cells), and control mice treated with PSGL-1–blocking mAb 4RA10 (dashed line, 114 cells). Core2^−/− mice treated with 4RA10 showed no rolling.

This Feature Is Available To Subscribers Only